CRISPR Therapeutics AG CRSP Stock Analysis
- Nasdaq
- Stock
- Market closed · opens Monday 9:30 AM ET
$50.07 up $1.51, 3.11% at close Nov 6
Last close · Previous close $48.56
- Market cap
- At the Nov 6 close
- P/E ratio
- n/mLoss over last 12 months
- Diluted EPS
- −$4.72Last 12 months
- Dividend yield
- NoneLast 12 months
Price chart
$50.07up $1.51, 3.11%Fri, Nov 6 session
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$48.56Nov 5
- Volume1.23MNov 6 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume1.37MLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $44.12 to $63.45; now $50.07
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Nov 6 close. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
CRSP beat the S&P 500 in 1 of 7 periods.
| Period | CRSP and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | CRSP: down 7.3% S&P 500: down 5.6% | CRSP trailed the S&P 500 by 1.7 percentage points Trailed |
| 3M | CRSP: down 3.0% S&P 500: down 4.1% | CRSP beat the S&P 500 by 1.1 percentage points Beat |
| YTD | CRSP: down 4.5% S&P 500: up 8.7% | CRSP trailed the S&P 500 by 13.2 percentage points Trailed |
| 1Y | CRSP: down 11.6% S&P 500: up 10.9% | CRSP trailed the S&P 500 by 22.5 percentage points Trailed |
| Long term | ||
| 3Y | CRSP: down 2.9% S&P 500: up 75.0% −1.0% vs +20.5% a year | CRSP trailed the S&P 500 by 77.9 percentage points Trailed |
| 5Y | CRSP: down 44.5% S&P 500: up 67.8% −11.1% vs +10.9% a year | CRSP trailed the S&P 500 by 112.3 percentage points Trailed |
| 10Y | CRSP: up 229.4% S&P 500: up 313.1% +12.7% vs +15.2% a year | CRSP trailed the S&P 500 by 83.7 percentage points Trailed |
$10,000 invested in CRSP 10 years ago (Nov 4, 2016) would be worth about $32,941 at the close on , with dividends reinvested. The same amount in the S&P 500 would be worth about $41,313.
CRSP beat the S&P 500 in 1 of 7 periods.
| Period | CRSP and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | CRSP: down 7.3% S&P 500: down 5.6% | CRSP trailed the S&P 500 by 1.7 percentage points Trailed |
| 3M | CRSP: down 3.0% S&P 500: down 4.3% | CRSP beat the S&P 500 by 1.3 percentage points Beat |
| YTD | CRSP: down 4.5% S&P 500: up 7.8% | CRSP trailed the S&P 500 by 12.3 percentage points Trailed |
| 1Y | CRSP: down 11.6% S&P 500: up 9.7% | CRSP trailed the S&P 500 by 21.3 percentage points Trailed |
| Long term | ||
| 3Y | CRSP: down 2.9% S&P 500: up 68.8% −1.0% vs +19.1% a year | CRSP trailed the S&P 500 by 71.7 percentage points Trailed |
| 5Y | CRSP: down 44.5% S&P 500: up 56.9% −11.1% vs +9.4% a year | CRSP trailed the S&P 500 by 101.4 percentage points Trailed |
| 10Y | CRSP: up 229.4% S&P 500: up 252.6% +12.7% vs +13.4% a year | CRSP trailed the S&P 500 by 23.2 percentage points Trailed |
$10,000 invested in CRSP 10 years ago (Nov 4, 2016) would be worth about $32,941 at the close on , not counting dividends. The same amount in the S&P 500 would be worth about $35,257.
All-time high
$210.04
Closing high on . Now 76.2% below that record.
Split-adjusted daily closes since Oct 19, 2016.
Stock splits
CRSP hasn’t split since its price history begins in 2016.
Valuation
Financials
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q3 FY26, the quarter ended Sep 30, 2026. “Last 12 months” means the four quarters from Oct 1, 2025 to Sep 30, 2026, and balance-sheet figures are as of Sep 30, 2026.
Revenue and net income
Last 12 months, with the change from the 12 months before
- Revenue
- $25.17Mdown 34.3%
- Net income
- −$456.14M
- Diluted EPS
- −$4.72
Data table
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q4 FY24 (Dec 31, 2024) | $35.69M | −$37.31M | −$0.42 |
| Q1 FY25 (Mar 31, 2025) | $865.00K | −$136.00M | −$1.58 |
| Q2 FY25 (Jun 30, 2025) | $892.00K | −$208.55M | −$2.40 |
| Q3 FY25 (Sep 30, 2025) | $889.00K | −$106.44M | −$1.17 |
| Q4 FY25 (Dec 31, 2025) | $864.00K | −$130.61M | −$1.35 |
| Q1 FY26 (Mar 31, 2026) | $1.46M | −$122.93M | −$1.28 |
| Q2 FY26 (Jun 30, 2026) | $10.18M | −$91.15M | −$0.94 |
| Q3 FY26 (Sep 30, 2026) | $12.67M | −$111.44M | −$1.15 |
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| FY21 (Dec 31, 2021) | $914.96M | $377.66M | $4.70 |
| FY22 (Dec 31, 2022) | $1.20M | −$650.18M | −$8.36 |
| FY23 (Dec 31, 2023) | $371.21M | −$153.61M | −$1.94 |
| FY24 (Dec 31, 2024) | $37.31M | −$366.25M | −$4.34 |
| FY25 (Dec 31, 2025) | $3.51M | −$581.60M | −$6.47 |
Margins
- Gross 100.0%
- Operating −2,114.8%
- Net −1,812.1%
The percentages above the chart cover the last 12 months; the lines show each quarter. What margins tell you
Cash flow
- −$376.72MLast 12 months
Cash from operations minus capital spending: the cash left after the business maintains and grows its assets.
FCF = Operating cash flow − Capital spendingFree cash flow - Operating cash flow−$374.63MLast 12 months
- Capital spending$2.08MLast 12 months
- −1,496.6%Last 12 months
Free cash flow as a share of revenue, both over the last 12 months.
Shareholder returns
- $134.61MLast 12 months
Cash spent repurchasing shares, net of shares issued. Buybacks shrink the share count, so each remaining share owns more of the company.
- Dividends paid$0.00Last 12 months
- Total returned$0.00Last 12 months
Balance sheet
- $2.28BAs of Sep 30, 2026
Cash plus short- and long-term marketable securities on the Sep 30, 2026 balance sheet.
- Total debt$779.83MAs of Sep 30, 2026
- Net cash$1.50BAs of Sep 30, 2026
- 16.21As of Sep 30, 2026
Current assets divided by current liabilities on the Sep 30, 2026 balance sheet. Above 1 means short-term assets cover the bills due within a year.
Current ratio = Current assets ÷ Current liabilitiesCurrent ratio - 0.47As of Sep 30, 2026
Total debt divided by shareholders’ equity on the Sep 30, 2026 balance sheet: a measure of financial leverage.
D/E = Total debt ÷ Shareholders’ equityDebt-to-equity ratio
Financial strength
- 2 of 9Last 12 months
vs the 12 beforeA 0–9 checklist from accounting professor Joseph Piotroski. Each test compares the last 12 months with the 12 months before and scores a point if it passes. 8–9 is strong; 0–2 is weak.
- ✗Net income was positive: not passed
- ✗Operating cash flow was positive: not passed
- ✓Return on assets improved: passed
- ✓Operating cash flow exceeded net income: passed
- ✗Long-term debt fell relative to assets: not passed
- ✗Current ratio improved: not passed
- ✗Share count didn’t rise: not passed
- ✗Gross margin improved: not passed
- ✗Asset turnover (revenue ÷ assets) improved: not passed
- −25.6%Last 12 months
Over the last 12 months, CRISPR Therapeutics lost money: its net loss was 25.6% of its shareholders’ equity (averaged over the last four quarter-ends). It describes the past year, not an expected return.
ROE = Net income (last 12 months) ÷ Average equityReturn on equity - −17.9%Last 12 months
Over the last 12 months, CRISPR Therapeutics’s net loss was 17.9% of its total assets (averaged over the last four quarter-ends).
ROA = Net income (last 12 months) ÷ Average total assets
About CRISPR Therapeutics AG
Since its inception over a decade ago, CRISPR Therapeutics has transformed from a research-stage company advancing programs in the field of gene editing, to a company that celebrated the historic approval of the first-ever CRISPR-based therapy in 2023 and has a diverse portfolio of product candidates across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, cardiovascular, autoimmune, and rare diseases. CRISPR Therapeutics advanced the first-ever CRISPR/Cas9 gene-edited therapy into the clinic in 2018 to investigate the treatment of sickle cell disease or transfusion-dependent beta thalassemia, and beginning in late 2023, CASGEVY™ (exagamglogene autotemcel [exa-cel]) was approved in some countries to treat eligible patients with either of those conditions. The Nobel Prize-winning CRISPR science has revolutionized biomedical research and represents a powerful, clinically validated approach with the potential to create a new class of potentially transformative medicines. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic partnerships with leading companies including Bayer and Vertex Pharmaceuticals. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Boston, Massachusetts and San Francisco, California, and business offices in London, United Kingdom.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Switzerland
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- Nasdaq
- Asset type
- Common stock
- Price history since
CRSP news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
CRSP stock FAQ
What is CRSP stock’s price today?
CRISPR Therapeutics (CRSP) traded at $50.07 at the close on , up $1.51 (3.11%) from the previous close of $48.56. Over the past 52 weeks it has traded between $44.12 and $63.45.
If you invested $1,000 in CRSP 10 years ago, how much would you have now?
With dividends reinvested, $1,000 invested in CRSP on would be worth about $3,294 at the close on , a total return of +229.4%. The same $1,000 would be worth $555 if invested five years ago and $884 if invested one year ago. Past performance doesn’t predict future returns.
What is CRSP’s P/E ratio?
CRSP’s P/E ratio isn’t meaningful right now because its earnings over the four quarters to are negative (diluted EPS of −$4.72).
How much revenue does CRISPR Therapeutics make?
CRISPR Therapeutics reported $25.2 million of revenue over the four quarters to , down 34.3% from the twelve months before. In its latest quarter (Q3 FY26, ended ) revenue was $12.7 million, up 1,325.1% from a year earlier.
Is CRISPR Therapeutics profitable?
Not over the four quarters to . CRISPR Therapeutics reported a net loss of $456.1 million across those four quarters on $25.2 million of revenue.
What are CRSP’s earnings per share?
CRSP’s diluted earnings per share were −$4.72 over the four quarters to , compared with −$5.57 in the twelve months before. The latest quarter (Q3 FY26) brought −$1.15 per share, against −$1.17 a year earlier (how EPS works).
Does CRSP pay a dividend?
CRISPR Therapeutics hasn’t paid a dividend in the last twelve months.
What is CRSP’s 52-week high and low?
Over the past 52 weeks CRSP has traded as low as $44.12 and as high as $63.45. At $50.07 at the close on , it is 21.1% below that high and 13.5% above the low.
What is CRSP’s all-time high?
CRSP’s highest closing price was $210.04 on , adjusted for stock splits. At $50.07 at the close on , it is 76.2% below that record.
Has CRSP stock ever split?
No. CRSP hasn’t split since its price history begins in 2016.
How has CRSP stock performed?
Including dividends and measured to the close on , CRSP has returned −4.5% so far this year and −11.6% over the past year, and −44.5% over five years (−11.1% a year). Over the same periods the S&P 500, measured by SPY, returned +8.7%, +10.9% and +67.8%. Past performance doesn’t predict future returns.
What sector and industry is CRISPR Therapeutics in?
CRISPR Therapeutics is in the Healthcare sector and the Biotechnology industry, and is headquartered in Switzerland.
What exchange does CRSP trade on?
CRISPR Therapeutics trades on the Nasdaq under the ticker symbol CRSP. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.